The NIMO Scandinavian Study: A Prospective Observational Study of Iron Isomaltoside Treatment in Patients with Iron Deficiency

Svein Oskar Frigstad, Anne Haaber, Antal Bajor, Jan Fallingborg, Per Hammarlund, Ole K Bonderup, Håkan Blom, Terje Rannem, Per M Hellström, Svein Oskar Frigstad, Anne Haaber, Antal Bajor, Jan Fallingborg, Per Hammarlund, Ole K Bonderup, Håkan Blom, Terje Rannem, Per M Hellström

Abstract

Background: Intravenous iron allows for efficient and well-tolerated treatment in iron deficiency and is routinely used in diseases of the gastrointestinal tract.

Objective: The aims of this study were to determine the probability of relapse of iron deficiency over time and to investigate treatment routine, effectiveness, and safety of iron isomaltoside.

Methods: A total of 282 patients treated with iron isomaltoside were observed for two treatments or a minimum of one year.

Results: Out of 282 patients, 82 had Crohn's disease and 67 had ulcerative colitis. Another 133 patients had chronic blood loss, malabsorption, or malignancy. Patients who received an iron isomaltoside dose above 1000 mg had a 65% lower probability of needing retreatment compared with those given 1000 mg. A clinically significant treatment response was shown, but in 71/191 (37%) of patients, anaemia was not corrected. The mean dose given was 1100 mg, lower than the calculated total iron need of 1481 mg. Adverse drug reactions were reported in 4% of patients.

Conclusion: Iron isomaltoside is effective with a good safety profile, and high doses reduce the need for retreatment over time. Several patients were anaemic after treatment, indicating that doses were inadequate for full iron correction. This trial is registered with NCT01900197.

Figures

Figure 1
Figure 1
Patient flow diagram (based on CONSORT 2010). CD: Crohn's disease; IBD: inflammatory bowel disease; UC: ulcerative colitis.
Figure 2
Figure 2
Probability of retreatment related to iron isomaltoside dose. The survival plot was obtained by using the Cox proportional hazards model with dose and diagnosis as factors and baseline haemoglobin as covariate. The probability (percent) of retreatment with iron isomaltoside at 52 weeks after the first treatment for each dose group was calculated from the survival curve. The number of patients at weeks 0, 52, and 100 for each dose group includes all patients.
Figure 3
Figure 3
Change in haemoglobin (Hb) after the first iron isomaltoside treatment in anaemic patients with available pre- and posttreatment Hb measures. The time of evaluation corresponded to the time between the last administration of first iron isomaltoside treatment and blood test follow-up and occurred during a mean (SD) time of 7.1 (6.0) weeks for anaemic patients at baseline and during a mean (SD) time of 6.1 (4.7) weeks for patients with Hb p value calculations were obtained by analysis of covariance test with diagnosis and dose as factors and pretreatment laboratory parameter concentration as covariate.

References

    1. Bager P., Befrits R., Wikman O., et al. The prevalence of anemia and iron deficiency in IBD outpatients in Scandinavia. Scandinavian Journal of Gastroenterology. 2011;46(3):304–309. doi: 10.3109/00365521.2010.533382.
    1. Bager P., Befrits R., Wikman O., et al. High burden of iron deficiency and different types of anemia in inflammatory bowel disease outpatients in Scandinavia: a longitudinal 2-year follow-up study. Scandinavian Journal of Gastroenterology. 2013;48(11):1286–1293. doi: 10.3109/00365521.2013.838605.
    1. Lupu A., Diculescu M., Diaconescu R., et al. Prevalence of anemia and iron deficiency in Romanian patients with inflammatory bowel disease: a prospective multicenter study. Journal of Gastrointestinal and Liver Diseases. 2015;24(1):15–20. doi: 10.15403/jgld.2014.1121.lpu.
    1. Ott C., Liebold A., Takses A., Strauch U. G., Obermeier F. High prevalence but insufficient treatment of iron-deficiency anemia in patients with inflammatory bowel disease: results of a population-based cohort. Gastroenterology Research and Practice. 2012;2012:7. doi: 10.1155/2012/595970.595970
    1. Bergamaschi G., Di Sabatino A., Albertini R., et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-α treatment. Haematologica. 2010;95(2):199–205. doi: 10.3324/haematol.2009.009985.
    1. Weisshof R., Chermesh I. Micronutrient deficiencies in inflammatory bowel disease. Current Opinion in Clinical Nutrition and Metabolic Care. 2015;18(6):576–581. doi: 10.1097/MCO.0000000000000226.
    1. Goldberg N. D. Iron deficiency anemia in patients with inflammatory bowel disease. Clinical and Experimental Gastroenterology. 2013;6:61–70. doi: 10.2147/ceg.s43493.
    1. Gisbert J. P., Gomollon F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. The American Journal of Gastroenterology. 2008;103(5):1299–1307. doi: 10.1111/j.1572-0241.2008.01846.x.
    1. Wells C. W., Lewis S., Barton J. R., Corbett S. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflammatory Bowel Diseases. 2006;12(2):123–130. doi: 10.1097/01.MIB.0000196646.64615.db.
    1. Stein J., Bager P., Befrits R., et al. Anaemia management in patients with inflammatory bowel disease: routine practice across nine European countries. European Journal of Gastroenterology & Hepatology. 2013;25(12):1456–1463. doi: 10.1097/MEG.0b013e328365ca7f.
    1. Pizzi L. T., Weston C. M., Goldfarb N. I., et al. Impact of chronic conditions on quality of life in patients with inflammatory bowel disease. Inflammatory Bowel Diseases. 2006;12(1):47–52. doi: 10.1097/01.mib.0000191670.04605.e7.
    1. Czuber-Dochan W., Ream E., Norton C. Review article: description and management of fatigue in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. 2013;37(5):505–516. doi: 10.1111/apt.12205.
    1. Dignass A. U., Gasche C., Bettenworth D., et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. Journal of Crohn’s & Colitis. 2015;9(3):211–222. doi: 10.1093/ecco-jcc/jju009.
    1. Van Assche G., Dignass A., Bokemeyer B., et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. Journal of Crohn’s & Colitis. 2013;7(1):1–33. doi: 10.1016/j.crohns.2012.09.005.
    1. Lindgren S., Wikman O., Befrits R., et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator-blind, multicentre study. Scandinavian Journal of Gastroenterology. 2009;44(7):838–845. doi: 10.1080/00365520902839667.
    1. Bonovas S., Fiorino G., Allocca M., et al. Intravenous versus oral iron for the treatment of anemia in inflammatory bowel disease: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 2016;95(2, article e2308) doi: 10.1097/MD.0000000000002308.
    1. Stein J., Dignass A. U. Management of iron deficiency anemia in inflammatory bowel disease - a practical approach. Annals of Gastroenterology. 2013;26(2):104–113.
    1. Reinisch W., Altorjay I., Zsigmond F., et al. A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease. Scandinavian Journal of Gastroenterology. 2015;50(10):1226–1233. doi: 10.3109/00365521.2015.1031168.
    1. Kulnigg S., Teischinger L., Dejaco C., Waldhor T., Gasche C. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. The American Journal of Gastroenterology. 2009;104(6):1460–1467. doi: 10.1038/ajg.2009.114.
    1. Evstatiev R., Alexeeva O., Bokemeyer B., et al. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clinical Gastroenterology and Hepatology. 2013;11(3):269–277. doi: 10.1016/j.cgh.2012.10.013.
    1. Blumenstein I., Dignass A., Vollmer S., Klemm W., Weber-Mangal S., Stein J. Current practice in the diagnosis and management of IBD-associated anaemia and iron deficiency in Germany: the German AnaemIBD Study. Journal of Crohn’s & Colitis. 2014;8(10):1308–1314. doi: 10.1016/j.crohns.2014.03.010.
    1. Ganzoni A. M. Intravenous iron-dextran: therapeutic and experimental possibilities. Schweizerische Medizinische Wochenschrift. 1970;100(7):301–303.
    1. DeMaeyer E. M., Joint WHO/UNICEF Nutrition Support Programme . Preventing and Controlling Iron Deficiency Anaemia Through Primary Health Care : a Guide for Health Administrators and Programme Managers. Geneva: World Health Organization; 1989.
    1. WHO. Iron Deficiency Anemia: Assessement, Prevention and Control. Geneva: World Health Organization; 2001.
    1. EMA. Directive 2001/20/EC of the European Parliament and of the Council Article 2(c) Luxembourg: European Medicines Agency; 2001.
    1. Befrits R., Wikman O., Blomquist L., et al. Anemia and iron deficiency in inflammatory bowel disease: an open, prospective, observational study on diagnosis, treatment with ferric carboxymaltose and quality of life. Scandinavian Journal of Gastroenterology. 2013;48(9):1027–1032. doi: 10.3109/00365521.2013.819442.
    1. Reinisch W., Staun M., Tandon R. K., et al. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED) The American Journal of Gastroenterology. 2013;108(12):1877–1888. doi: 10.1038/ajg.2013.335.
    1. Khalil A., Goodhand J. R., Wahed M., Yeung J., Ali F. R., Rampton D. S. Efficacy and tolerability of intravenous iron dextran and oral iron in inflammatory bowel disease: a case-matched study in clinical practice. European Journal of Gastroenterology & Hepatology. 2011;23(11):1029–1035. doi: 10.1097/MEG.0b013e32834a58d1.
    1. Cortes X., Borras-Blasco J., Moles J. R., Bosca M., Cortes E. Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study. PLoS One. 2015;10(5, article e0128156) doi: 10.1371/journal.pone.0128156.
    1. Garcia-Lopez S., Bocos J. M., Gisbert J. P., et al. High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: early efficacy and impact on quality of life. Blood Transfusion. 2016;14(2):199–205. doi: 10.2450/2016.0246-15.
    1. Dahlerup J. F., Jacobsen B. A., van der Woude J., Bark L. A., Thomsen L. L., Lindgren S. High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23. Scandinavian Journal of Gastroenterology. 2016;51(11):1332–1338. doi: 10.1080/00365521.2016.1196496.
    1. Bager P., Hvas C. L., Dahlerup J. F. Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions. British Journal of Clinical Pharmacology. 2017;83(5):1118–1125. doi: 10.1111/bcp.13189.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi